BioGAL is developing an innovative treatment for multiple myeloma
(MM), an incurable hematological cancer of plasma cells.
Employees: 9
Overview
BioGAL is a market-driven developer of drug applications for
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
cancer.
The Company has patented (PCT, pending) the use of
Erythropoietin (EPO) against Multiple Myeloma (MM), an incurable
hematological cancer of plasma cells.
BioGAL's observations are derived from initial clinical research
and basic science research on murine animal models. Following
clinical observation, the Company has carried out successful
animal studies on various scientifically accepted myeloma models.
EPO-treated mice lived significantly longer than controls,
suggesting that EPO has the ability to arrest or significantly
slow down MM disease processes. These findings are a result of
decades of work by BioGAL's scientific leaders, who have
dedicated years to the project, experimented with thousands of
mice on various animal models and earned the recognition of the
most respected scientific journals.
BioGAL is also examining the effect of EPO on additional
potential cancer types.
